Skip to content

A clinical study to evaluate the effectiveness of Manjistha Ghrita Malahara in the management of scar.

A Randomized controlled Trail to evaluate the efficacy of Manjistha Ghrita Malahara in the management of scar. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104702
Enrollment
30
Registered
2026-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L819- Disorder of pigmentation, unspecified

Interventions

None listed

Sponsors

Dr. Ravi Kumar S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Patients aged between 18 to 60 years, of either gender. ii. Presence of post-traumatic and post-surgical scars. iii. Wound in the remodeling phase. iv. Scars should be flat, superficial or slightly elevated, non-infected, and non-keloidal. v. The size of the scar should be leeser than oe equal to 5 cm in length and leeser than or equal to 5 cm in width. vi. Willing to participate voluntarily and provide informed written consent. vii. Patients available for regular follow-up during the study period.

Exclusion criteria

Exclusion criteria: i. Patients aged less than 18 years and more than 60 years, irrespective of the gender. ii. Wound in the stages of haemostasis, inflammation, and proliferation. iii. Patients with keloids or genetical predisposition of keloids. iv. Scars associated with infection, discharge, or ulceration. v. Scars larger than 5 cm in length or greater than 5 cm in width. vi. Known hypersensitivity to Manjishta and MINISCAR cream. vii. Patients with chronic dermatological conditions (e.g., eczema, psoriasis, vitiligo) affecting the scar site. viii. Patients with systemic illness, autoimmune diseases, immunocompromised state or on long-term steroids or immunosuppressants.

Design outcomes

Primary

MeasureTime frame
Management of the scar without complications.Timepoint: Management of the scar without complications.

Secondary

MeasureTime frame
Improvement in the Quality of Life.Timepoint: Day 1: Before treatment [BT]. Day 15: During the treatment [DT] Day 30: After the treatment [AT].

Countries

India

Contacts

Public ContactDr Ravi Kumar S

Shri Dharmasthala Manjunatheshwara Institute of Ayurveda and Hospital, Bengaluru

mahamanjunathnaregal@gmail.com9008695898

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026